Eli Lilly announced that the experimental drug donanemab showed significant benefits for early Alzheimer's disease patients.
Alzheimer's disease affects tens of millions of people every year, slowly stripping away cognitive function. Now, a new drug trial by Eli Lilly might be the best hope yet of slowing the inevitable progression of the disease.
The drug, donanemab, "significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease," according to anannouncing the trial results.
Among trial participants, nearly half of those receiving donanemab experienced no measurable worsening of symptoms after one year , compared to 29% of participants who were on placebo.
In intermediate and advanced Alzheimer's disease cases, participants show a 29% and 22% slower progression of symptoms, respectively, so even those who have already progressed significantly into the later stages of the disease stand to benefit from the new drug., it is possible to overhype any progress toward a treatment.
"It's modest, but I think it's real," Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, told
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Read more »
Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Read more »
Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Read more »
Eli Lilly says experimental drug slows Alzheimer's worseningEli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease
Read more »
Experimental Alzheimer's drug slows cognitive declines in large trial, drugmaker Eli Lilly says | CNNAn experimental Alzheimer's medication slowed declines in patients' ability to think clearly and perform daily tasks by more than a third in a large clinical trial, drugmaker Eli Lilly said Wednesday.
Read more »
Eli Lilly says its experimental Alzheimer's drug appears to slow symptomsEli Lilly said its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease.
Read more »